Urinary NT-proBNP level: Relationship with ventricular function parameters in heart failure;NT-proBNP en orina y su relación con los parámetros de la función ventricular en la insuficiencia cardiaca

Revista Espanola de Cardiologia

Volumn 60, Issue 5, 2007, Pages 510-516

  Roselló Lletí, Esther ^a   Rivera Otera, J Miguel ^a,g   Miró, Vicente ^a   Mor, Vicente ^b   Cortés, Raquel ^a   Lauwers, Catheline ^c   Velero, Ricardo ^d   Sevilla, Begoña ^b   Sogorb, Francisco ^e   Morillas, Pedro ^d   de Burgos, García ^f   Portlés, Manuel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c Hospital San Francesc de Borja   (Spain)

^d HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^g Hospital de Elche ^*  (Spain)

Author keywords

Echocardiography; Heart failure; Natriuretic peptides

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); UNCLASSIFIED DRUG;

AGED; ARTICLE; ATRIOVENTRICULAR CANAL; BIOCHEMISTRY; BLOOD FLOW VELOCITY; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; MULTIPLE LINEAR REGRESSION ANALYSIS; PREDICTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE LEVEL; BLOOD; ECHOGRAPHY; FORWARD HEART FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

AGED; ALDOSTERONE; BIOLOGICAL MARKERS; CARDIAC OUTPUT, LOW; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; VENTRICULAR FUNCTION;

EID: 34250880146     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(07)75068-6     Document Type: Article

References (34)

1. The task force on heart failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J. 1995;16:741-51.
2. Bettencourt P. Brain natriuretic peptide (nesiritide) in the treatment of heart failure. Cardiovasc Drug Rev. 2002;20:27-36.
3. Tokmakova M, Solomon SD. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol. 2006;21:268-72.
4. Prasad SK, Dargie HJ, Smith GC, Barlow MM, Grothues F, Groenning BA, et al. Comparison of the dual receptor endothelin antagonist enrasertan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart. 2006;92:798-808.
5. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left- ventricular systolic dysfunction. Lancet. 1998;351:9-13.
6. Anguita M, Monies P, Jordán A, Casares G, Gómez I, Recio J, et al. Utilidad de NT-proBNp en el diagnóstico de insuficiencia cardiaca en una población heterogénea de pacientes con disnea. Rev Esp Cardiol. 2006;59:465-72.
7. Chen AA, Wood MJ, Krauser DG, Baggish AL, Tung R, Anwaruddin S, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the proBNP Investigation of Dyspnea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J. 2006;27:839-45.
8. Sudoch T, Kangawak K, Minamino, N, Matsuo M. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81.
9. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-12.
10. Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy and left ventricular systolic dysfunction on plasma N-terminal proBNP. Heart. 2000;83:278-82.
11. Ng LL, Loke IW, Davies JE, Geeranavar S, Khunti K, Stone MA, et al. Community Screening for left ventricular dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol. 2005; 45:1043-50.
12. Cortés R, Portolés M, Salvador A, Bertomeu V, García de Burgos F, Martínez-Dolz L, et al. Diagnostic and pronostic value of urine NT-proBNP levels in heart failure patients. Eur J Heart Fail. 2006;8:621-7.
13. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26: 1115-40.
14. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490-8.
15. García MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol. 1998;32:865-75.
16. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-67.
17. Willenheimer R, Cline C, Erhardt L, Israelsson B. Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure. Heart. 1997;78:230-6.
18. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail. 2004;6:365-8.
19. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardionyopathy. Circulation. 1993;88:372-80
20. Yamamoto K, Burnett JC, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-94.
21. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terrninal-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47:287-96.
22. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol. 2004;43:416-22.
23. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med. 2001;39:571-88.
24. Totsune K, Takahashi K, Satoh F, Sone M, Ohmeda M, Satoh C, et al. Urinary immunoreactive brain natriuretic peptide in patients with renal disease. Regul Pept. 1996;63:141-7.
25. Nakao O, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens. 1992;10:1111-4.
26. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol. 2003;285:F167-77.
27. Togashi K, Fujita S, Kawakami M. Presence of brain natriuretic peptide in urine. Clin Chem. 1992;39:322-3.
28. Heringlake M, Heide C, Bahlmarm L, Eighler W, Pagel H, Schmucker P, et al. Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers. J Appl Physiol. 2004;97:173-9.
29. Kranidis A, Kostopoulos K, Anthopoulos L. Evaluation of left ventricular filling by echocardiographic atrioventricular plane displacement in patients with ischemic heart disease. Int J Cardiol. 1995;48:183-6.
30. Willenheimer R, Cline C, Erhardt L, Israelsson B. Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure. Heart. 1997;78:230-6.
31. Willenheinier R, Israelsson B, Cline C, Rydberg E, Broms K, Erhardt L. Left atrioventricular plane displacement is related to both systolic and diastolic left ventricular performance in patients with chronic heart failure. Eur Heart J. 1999;20:612-8.
32. Eicken A, Fratz S, Gutfried C, Balling G, Schwaiger M, Lange R, et al. Hearts late after fontan operation have normal mass, normal volume, and reduced systolic function: a magnetic resonance imaging study. J Am Coll Cardiol. 2003;42:1061-5.
33. Siu SC, Rivera JM, Guerrero JL, Handschumacher MD, Lethor JP, Weyman AE, et al. Three-dimensional echocardiography. In vivo validation for left ventricular volume and function. Circulation. 1993;88:1715-23.
34. Siu SC, Levine RA, Rivera JM, Xie SW, Lethor JP, Handschumacher MD, et al. Three-dimensional echocardiography improves noninvasive assessment of left ventricular volume and performance. Am Heart J. 1995;130:812-22.